Skip to main navigation

Search for:

Search

Rubius Therapeutics

About Us
Our Science
Our Pipeline
Investors & Media
Careers
Contact

Menu Search

Press Releases

Year

September 19, 2022

Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

September 13, 2022

Rubius Therapeutics Announces Strategic Update

September 12, 2022

Rubius Therapeutics to Provide Strategic Update

August 9, 2022

Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

July 26, 2022

Rubius Therapeutics to Announce Second Quarter 2022 Financial Results

July 14, 2022

Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors

June 22, 2022

Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting

June 1, 2022

Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference

May 26, 2022

Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting

May 24, 2022

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 21

Print Page

RSS Feeds

Share Page

Email Alerts

Contact Us

399 Binney St, Suite 300
Cambridge, MA 02139 617-679-9600

Share

LinkedIn Twitter YouTube FaceBook

Home
About Us
Our Science
Our Pipeline
Investors
Careers
Sitemap
Terms of Use
Privacy Policy

© Rubius Therapeutics, Inc. 2022. All Rights Reserved. RUBIUS and RED PLATFORM are registered trademarks of Rubius Therapeutics, Inc. RUBIUS THERAPEUTICS, RED CELL THERAPEUTICS and RCT are trademarks of Rubius Therapeutics, Inc. All other trademarks referenced herein are the properties of their respective owners.

Facebook
Twitter
LinkedIn